缬沙坦治疗轻中度原发性高血压的临床效果与安全性

目的：观察缬沙坦的临床降压效果及其安全性。方法：102例临床确诊为轻、中度高血压病人选，并随机分为缬沙坦组(55人)和氯沙坦组(47人)。前每日晨服缬沙坦80mg，后每日晨服氯沙坦50mg，总治疗时间为8周。期间定期测定血压，并于治疗开始前与服药第8周测定病人的血钾及肝、肾功能。结果：服药第4周、第8周两组血压均较治疗前显降低(P＜0．01)。到第8周末，缬沙坦组与氯沙坦组降压总有效率分别达91％与87％。与治疗开始前比较，第8周末病人的血钾，肝、肾功能无明显改变。结论：缬沙坦和氯沙坦对轻、中度高血压病人有良好的治疗效果，服用安全。

Clinical effect iveness and safety of valsartan in treatment of patients with mild or moderate essential hypertension

Objective: To evaluate the clinical effect ivess and safety of valsartan in treatment of patients with mild to moderate essential hypertension. Methods: One hundred and two patients with essential hypertension were enrolled in this clinical pharmacological trial and randomly divided into valsartan group ( n =55) and losartan group ( n =47). In the evaluating period of 8 weeks, each patient in valsartan group took 80 mg of valsartan and the patient in losartan group took 50 mg of losartan every morning. Their blood pressure was measured periodically. The blood potassium level, liver function and renal function were examined before the trial and after 8 weeks. Results: Compared with before the trial the blood pressure of both groups decreased significantly after 4 and 8 weeks of the trial ( P <0.01). The blood potassium level,liver function and renal function had no obviously difference between before and after the trial. Conclusion: Valsartan like losartan may be used in the antihypertension treatment of patients with essential hypertension effectively and safely.